Spectrum Pharmaceuticals Inc has received the FDA approval for its Zevalin as a treatment for non-Hodgkin’s lymphoma, a blood cancer. Zevalin was previously used only for patients who had tumors that had not responded to other treatments. The FDA approval was granted on the basis of a phase-three study in which 414 patients showed partial or complete response after receiving a first-line chemotherapy regimen and Zevalin.